Close

Search

12

2012 Conference Call Minutes

minutes cpic april 5 2012 minutes cpic Dec 6 2012 minutes cpic Feb 2 2012 minutes cpic June 8 2012 minutes cpic mar 1 2012 minutes cpic May 3 2012 minutes cpic Nov 1 2012 minutes cpic Oct 4 2012 minutes cpic Sept 13 2012 WGS_CPIC guideline 12062012 meeting_Huser

Read More

Term Standardization for Clinical Pharmacogenetic Test Results-Part 2

In 2016, CPIC led a consensus effort to standardize terms for clinical pharmacogenetic tests. The goal of the project was to create standardized terms for pharmacogenetic allele function and phenotypes to be used in CPIC guidelines (specifically Tables 1 and 2) and in the larger pharmacogenetics community (Term Standardization Part 1). However, additional standardization opportunities […]

Read More

2019 CPIC Conference Call Minutes

February 2019 CYP2C19-Proton Pump Inhibitors Oslin slides March 2019 CPIC Twitter 101 Monte slides April 2019 Giacomini slides May 2019 Hoshitsuki slides Bousman/Mueller slides August 2019 FDA/PGx slides September 2019 Allele function assignment SOP and CYP2C9 function assignment CYP2C9 Genotyping Recommendations: AMP Pharmacogenomics Working Group AMP Clinical Practice Committee October 2019 CPIC update slides Relling […]

Read More

CYP2D6 Genotype to Phenotype Standardization Project

Since pharmacogenetic clinical recommendations are based on phenotype, the assignment of phenotype based on genotype is an important aspect to clinical implementation and reporting of different inferred phenotypes across laboratories and guidelines has created considerable confusion and inconsistencies in recommendations. To maximize the utility of pharmacogenetic test results, it is desirable to standardize the phenotype […]

Read More

CPIC® Guideline for Atomoxetine based on CYP2D6 genotype

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) and between clinical genetic […]

Read More

CPIC® Guideline for Tamoxifen based on CYP2D6 genotype

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018)  Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) and between clinical genetic testing […]

Read More

Prioritization of CPIC Guidelines

Prioritizing the order of writing guidelines for CPIC genes/drugs is based on the following criteria: Is there prescribing actionability? What is the severity of the clinical consequences (adverse effects, lack of response) if genetics are not used to inform prescribing? Is the gene already subject to other CPIC guidelines? Is there an available genetic test […]

Read More

CPIC® Guideline for Ondansetron and Tropisetron based on CYP2D6 genotype

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016) Updates since publication: October 2019: CYP2D6 genotype to phenotype translation changes: Up until August 2019, there were a few inconsistencies in the translation of CYP2D6 genotype to phenotype across guidelines (i.e. CPIC and DPWG) […]

Read More

CPIC® Guideline for Phenytoin and CYP2C9 and HLA-B

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (November 2014) Updates since publication: No updates on dosing recommendations since publication. Tables and figure provided in the main manuscript of the guideline: Table 1. Assignment of likely phenotype based on diplotypes Table 2. Recommended dosing of […]

Read More

CPIC® Guideline for Clopidogrel and CYP2C19

Most recent guideline publication: Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 update (September 2013) Updates since publication: March 2017: The FDA-approved label for clopidogrel (Plavix) was recently updated (September 2016) and warns that patients who are CYP2C19 poor metabolizers may have diminished effectiveness of the drug as compared to patients […]

Read More